OncoTargets and Therapy (Jun 2020)

Insulin-Like Growth Factor Binding Protein-2 Promotes Proliferation and Predicts Poor Prognosis in Hepatocellular Carcinoma

  • Ma Y,
  • Cui D,
  • Zhang Y,
  • Han C,
  • Wei W

Journal volume & issue
Vol. Volume 13
pp. 5083 – 5092

Abstract

Read online

Yang Ma, Dongqian Cui, Yu Zhang, Chen-chen Han, Wei Wei Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-Inflammatory and Immune Medicine, Institute of Clinical Pharmacology, Anhui Medical University, Hefei, People’s Republic of ChinaCorrespondence: Wei WeiInstitute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Meishan Road 81, Hefei 230032, People’s Republic of ChinaTel +86-551-6516-1209Email [email protected]: Insulin-like growth factor binding protein-2 (IGFBP2) levels are significantly increased in the plasma of hepatocellular carcinoma (HCC) patients. However, the correlation between IGFBP2 levels and clinical parameters and the exact role of IGFBP2 in HCC are unclear. In this study, we identified the role and potential molecular mechanisms of IGFBP2 in HCC.Materials and Methods: ELISA assays were used to detect plasma IGFBP2 levels in HCC patients and healthy controls, and the correlations with patients’ clinicopathological data were analyzed. The CCK8 assay was used to explore cell proliferation. Luciferase reporter, co-immunoprecipitation, and immunofluorescence assays were used to demonstrate the molecular mechanism of IGFBP2 in HCC.Results: Plasma IGFBP2 levels were determined blindly in 37 HCC patients and 37 matched healthy controls. The mean plasma IGFBP2 concentrations in HCC patients were higher than in healthy controls, and IGFBP2 levels in HCC were positively correlated with the degree of differentiation, tumor size, metastasis, and portal venous invasion. Exogenous IGFBP2 activated integrin β 1 and thus induced the combination and colocalization of activated integrin β 1 and p-FAK, which promoted the phosphorylation of FAK, Erk, and Elk1, eventually inducing EGR1-mediated proliferation of the HCC cell lines HepG2 and HCCLM3. Meanwhile, neutralization of integrin β 1 inhibited IGFBP2-induced FAK, Erk, Elk1, and EGR1 activation.Conclusion: Taken together, these results indicated that exogenous IGFBP2 promoted the integrin β 1/FAK/Erk/Elk1/EGR1 pathway, which stimulated the proliferation of HCC cells. Plasma IGFBP2 could be a novel prognostic biomarker for HCC patients.Keywords: IGFBP-2, integrin β 1, FAK, HCC proliferation

Keywords